ViroStatics srl is a privately held bio-pharmaceutical company, headquartered in Sassari (Italy), with a successful history of fundraising and a large international network of partners and collaborators. Management has track record in Licensing and M&As. Its key operational field is oncology. Over the years, ViroStatics has developed a robust pipeline of proprietary compounds for several distinct disease indications (with initial focus on Breast cancer resistant to CDK4/6 inhibitors and Mesothelioma), all of them covered by patent protection towards 2039, characterized by their unique kinase selectivity, efficacy and safety profiles. ViroStatics is also still active in virology offering services to test drugs and devices against SARS-CoV-2. The company is led by a top-level team, with experience in the conduction of complex projects. Its expertise spans from basic science to clinical trials with over 100 published manuscripts and over 10 clinical trials coordinated (Phase I and Phase II). http://www.virostatics.com/